Home > Inhibitors & Agonists > Others
Cat. No. Product name CAS No.
DCC2849 Jnj-61432059

Novel TARP γ-8 Selective AMPAR Negative Modulator

2035814-50-5
DCC2850 Jnj-dgat1-a

Selective DGAT1 inhibitor

1092067-85-0
DCC2851 Jnj-dgat2-b

Selective DGAT2 inhibitor

DCC2852 Jns 1-40

Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth

DCC2853 Jp1201

Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner

DCC2854 Jp4-039

Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs)

1205492-16-5
DCC2855 Jr-220

Non-toxic anti-relapse agent, acamprosate

6933-71-7
DCC2856 Jra-003

Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC)

DCC2857 Jrc-ii-191

Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor

DCC2858 Js399-19

Novel specific inhibitor of Fusarium myosin I; Fungicide

39491-78-6
DCC2859 Jsf-2019

Novel antitubercular agent, inhibiting InhA and FAS-II pathway

DCC2860 Jsf-2513

Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway

DCC2861 Jsi287

Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway

DCC2862 Jte-151

Novel RORγ

1608139-41-8
DCC2863 Jte-607

Cytokine release inhibitor, inhibiting production of IL-1ß, IL-8, IL-6, IL-10 and TNFalpha

188791-71-1
DCC2864 Jtk-853

Novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase

954389-09-4
DCC2865 Jts-653

Novel orally active and selective transient receptor potential vanilloid 1 (TRPV1) antagonist

942614-99-5
DCC2866 Jtt-552

Novel inhibitor of urate transporter 1 (URAT1)

888730-46-9
DCC2867 jtv-506

Novel K(ATP) channel opener

170148-29-5
DCC2868 Jtv-803 Mesylate

Specific inhibitor of factor Xa

247131-79-9
DCC2869 Julolidine Phenoxazone Azide

Novel live-cell peobe of voltage-dependent structural changes of voltage-gated Kv2.1 channels

DCC2870 jwb1-84-1 Trihydrochloride

Novel neuroprotective agent, improving cognitive performances in a transgenic mouse model of AD

491878-69-4
DCC2871 Jwg-115

Novel BET selective inhibitor, targeting BRD4

DCC2872 Jwh-007

Potent cannabinoid (CB) receptor agonist

155471-10-6
DCC2873 Jwu-a021

Novel potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro, also potently stimulating Ca(2+) influx through TRPA1 cation channels, being one of the most potent non-electrophilic TRPA-1 channel agonists

1403610-23-0
DCC2874 Jxl069

Novel potent mitochondrial pyruvate carrier (MPC) inhibitor to treat hair loss

DCC2875 Jy-1-106

Novel BH3 α-helix mimetic, inducing apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak

DCC2876 Jyl-1511

High-affinity partial agonist of the vanilloid receptor

623166-14-3
DCC2877 Jyl-273

Potent TRPV1 agonist

1391826-17-7
DCC2878 Jyl-79

Potent vanilloid receptor (VR1) agonist

289902-64-3
DCC2879 Jy-xhe-053

Selective modulator of GABAA receptors containing the α5 subunit

612526-36-0
DCC2880 Jz-4109

Novel β-Glucocerebrosidase modulator, promoting dimerization of β-glucocerebrosidase and revealing an allosteric binding site, stabilizing wild-type and N370S mutant GCase and increases GCase abundance in patient-derived fibroblast cells

DCC2881 Jz-5029

Novel irreversible β-Glucocerebrosidase modulator

DCC2882 jzad-iv-22

Inhibitor of all three monoamine transporters

1333245-01-4
DCC2883 Jzp-430

Potent, highly selective, and irreversible ABHD6 Inhibitor

1672691-74-5
DCC2884 K00135

Novel potent and selective inhibitor of PIM kinases

869650-21-5
DCC2885 K00518

Novel dual CLK1 and CLK3 inhibitor

DCC2886 K103 Hydrochloride

Novel inhibitor of peptidoglycan synthesis targeting the lipid II precursor

1071544-43-8
DCC2887 K-14585

Novel antagonist for proteinase-activated receptor 2 (PAR2)

880546-17-8
DCC2888 K4610422

Novel norditerpenoid inhibitor of testosterone-5α-reductase

DCC2889 K-8008

Novel inhibitor of the interaction of the N-terminally truncated RXR

2276730-51-7
DCC2890 K-8012

Novel inhibitor of the interaction of the N-terminally truncated RXR

1346513-17-4
DCC2891 Kaempulchraol P

Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression

DCC2892 Kaempulchraol Q

Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression

DCC2893 Kalb001

Novel mGlu4 ligand

DCC2894 Kar425

Novel antimalarial agent, providing protection to malaria-infected mice

1809050-49-4
DCC2895 Kasugamycin

Antibiotic, binding within the mRNA channel of the 30S subunit and inhibiting protein synthesis

6980-18-3
DCC2896 Kb130015

Novel activator of hERG1 potassium channels, blocking native and recombinant hERG1 channels at high voltages, but activating them at low voltages

147030-48-6
DCC2897 Kbh-a42

Novel histone deacetylase inhibitor

798543-50-7
DCC2898 Kbjk557

Novel Plk1 PBD inhibitor, showing a remarkable in vitro anticancer effect by inducing Plk1 delocalization, mitotic arrest, and apoptosis in HeLa cells

DCC2899 Kb-nb165-09

Selective inhibitor of Protein_kinase_D1>protein kinase D (PKD); Inhibitor of cell adhesion and HIV; Inhibitor of herpes simplex virus type 1 replication

172832-10-9
DCC2900 Kbp-088

Novel highly potent dual amylin and calcitonin receptor agonist (DACRA), showing long-lasting improvement of food preference and body weight loss

DCC2901 Kb-r7785

Novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the in

168158-16-5
DCC2902 Kc-11404

LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor,and 5-lipoxygenase

148490-22-6
DCC2903 Kca075

Highly specific transglutaminase 2 (TG2) inhibitor

DCC2904 Kca-1490

Dual PDE3/4 inhibitor

909719-71-7
DCC2905 Kca2 Positive Modulator 2q

Novel potent and Subtype-Selective Positive Modulator of KCa2 Channels

DCC2906 Kcal01

Potent PDZ domain peptide inhibitor that rescues CFTR activity

DCC2907 Kdm4c-in-35

Novel selective KDM4C inhibitor

1841508-48-2
DCC2908 Kdm4-in-i

Novel KDM4 inhibitor

23705-85-3
DCC2909 Kdoam-20

Potent and selective KDM5 inhibitor

DCC2910 Kdoam-21

Potent and selective KDM5 inhibitor

DCC2911 Kemptide Acetate Salt

Phosphate acceptor peptide substrate for cAMP-dependent protein kinase

1629902-50-6
DCC2912 Kf15372

Potent and selective adenosine A1 antagonist with renal protective and diuretic activities

131080-42-7
DCC2913 Kfa1982

Novel and potent factor Xa inhibitor

409358-98-1
DCC2914 Kgchm07

Novel potent peptide dual agonist of opioid/neurokinin 1 receptor

DCC2915 Kh-carb13 Hydrochloride

Novel Pim-1 kinase Inhibitor, dose-dependent decreasing the viability of LS174T and HCT-116 cells

1353572-78-7
DCC2916 Khg21834

Inhibitor of Aβ-induced inflammation

940938-64-7
DCC2917 Khg26693

Novel anti-inflammatory and antioxidant agent, significantly decreasing blood glucose, triglycerides, and cholesterol and increased insulin

1497249-95-2
DCC2918 Ki23057

Novel FGFR2 inhibitor, enhancing the chemosensitivity of drug-resistant gastric cancer cell lines

516523-31-2
DCC2919 Kif18a Inhibitor 23

Novel KIF18A inhibitor, causing significant mitotic arrest in vivo, binding at the interface of KIF18A and tubulin

DCC2920 Ki-ms2-008

Novel Max-binding modulator, attenuating Myc-driven transcription and stabilizing the Max homodimer

DCC2921 kin100

Novel inducer of the ISG54 promoter, causing IRF-3 translocation

299952-11-7
DCC2922 Kir1.1-in-a

Novel potent and selective inhibitor of kir1.1 channels

DCC2923 Kist301072

Novel ROS1 kinase inhibitor

DCC2924 Kist301080

Novel ROS1 kinase inhibitor

DCC2925 Kjm429

Novel TRPV1 antagonist

401907-57-1
DCC2926 Kj-pyr-10

Novel specific inhibitor of MYC

DCC2927 Kkha-761

Potent D3 receptor antagonist with high 5-HT1A receptor affinity

DCC2928 Kl-1156

Novel NF-κB inhibitor and lipopolysaccharide (LPS)-induced nitric oxide production inhibitor

819868-62-7
DCC2929 Kld-12

Self-assembling peptide, forming a hydrogel matrix to support growth of cells in the presence of an ionic solution, enhancing chondrogenic differentiation of bone marrow stromal cells (BMSCs)

800379-47-9
DCC2930 Klebsazolicin

Novel inhibitor of 70S ribosome by obstructing the peptide exit tunnel

2257496-47-0
DCC2931 Klk6-in-32

First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro

DCC2932 Klk6-in-42

First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro

DCC2933 Kl-l9p

Novel antibiotic sensitizer, promoting the rearrangement of the bacterial membrane that enables hydrophobic antibiotics to permeate, strongly sensitizing Gram-negative bacteria to linezolid (Lzd), rifampicin (Rif), or clarithromycin (Clr)

DCC2934 Boc-phe-leu-glup(oph)

0

DCC2935 Km05382

CDK9 inhibitor, inhibiting transcription of GAPDH

882291-64-7
DCC2936 km10340

Selective S1P3 agonist

844635-76-3
DCC2937 Km-5-25

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

DCC2938 Km-5-66

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

DCC2939 kmi-1764

Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position

1469987-42-5
DCC2940 Kmn-010034

Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor

DCC2941 Kmn-80

Novel Potent and Selective EP4 Agonist

1628759-75-0
DCC2942 kms80013

Novel inhibitor of amyloid-

930284-65-4
DCC2943 Kms88009

Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder

1089681-42-4
DCC2944 Kmup-3

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

421556-16-3
DCC2945 Kmup-4

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

864873-81-4
DCC2946 Kongensin D

Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects

DCC2947 kp1212

Novel non-chain terminating nucleoside analog anti-HIV inhibitor

114522-16-6
DCC2948 Kpt-6604

Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer

DCC2949 Kpu-300

Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn.

1620692-60-5
DCC2950 Kr-12-a4

Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity

DCC2951 Kr-25210

Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus

DCC2952 Kr-31762

Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury

DCC2953 Kras(g12c)-in-1

Novel irreversible inhibitor of KRAS(G12C)

DCC2954 Kras4b-in-d14

Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells

924249-06-9
DCC2955 Kras4b-pdeδ Stabilizer C19

Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling

1049727-35-6
DCC2956 Krc-108

Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met

1146944-35-5
DCC2957 Krc-327

Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.

1350612-75-7
DCC2958 Krm-ii-08

Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c

DCC2959 Krn4884

Potassium channel opener

152802-84-1
DCC2960 Krn-8602 Hydrochloride

Topo II inhibitor, exhibiting cytotoxic effects against tumour cells

131722-57-1
DCC2961 Krp-109

Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes

1275996-50-3
DCC2962 Krp-199

Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo

221164-28-9
DCC2963 Krp-204

Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity

220475-76-3
DCC2964 Ks-133

Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders

DCC2965 Ksc-392-150

Novel inhibitor of the permeability transition pore (PTP)

DCC2966 kscm-1

Selective ligand of the sigma-1 receptor

1415247-17-4
DCC2967 Kscm-11

Ligand of the sigma receptor

1415247-16-3
DCC2968 kscm-5

Ligand of the sigma receptor

1415247-18-5
DCC2969 Ksk120

Novel inhibitor of transcriptional activity in Chlamydia trachomatis

1638100-63-6
DCC2970 Ksl-128114

Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma

DCC2971 Kspa-1

Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP

264207-32-1
DCC2972 Kt-182

Potent and selective inhibitor of ABHD6

1402612-62-7
DCC2973 Kt2-962

TXA2/prostaglandin endoperoxide receptor antagonist

129648-96-0
DCC2974 Kta-439

Thyroid hormone receptor β (TRβ) selective agonist

575503-70-7
DCC2975 Ku-2285

Hypoxic cell radiosensitizer

121077-11-0
DCC2976 Kufal194

Novel selective DYRK1A inhibitor

DCC2977 Kunb31

Novel potent and selective inhibitor of Hsp90β

2220263-80-7
DCC2978 Kurasoin B

Novel protein farnesyltransferase inhibitor

193696-42-3
DCC2979 kv1.5-in-iiii

Potent Kv1.5 inhibitor

1469902-72-4
DCC2980 Kv2.1/syntaxin-in-cpd5

Novel neuroprotectant, inhibiting Kv2.1-syntaxin molecular interaction

DCC2981 Kva-d-88

Novel Preferable Phosphodiesterase 4B (PDE4B) Inhibitor, Decreasing Cocaine-Mediated Reward Properties in Vivo

2410550-31-9
DCC2982 Ky1022

Ras destabilizer, targeting the Wnt/ß-catenin pathway and inhibiting development of metastatic colorectal cancer

1029721-36-5
DCC2983 Kya1797

Novel inhibitor of the Wnt/ß-catenin pathway, binding directly to the regulators of G-protein signaling domain of axin, initiating ß-catenin and Ras degradation through enhancement of the ß-catenin destruction complex activating GSK3ß, effectively suppres

851304-36-4
DCC2984 Kys05047

Selective T-type Ca(2+) channel blocker with anti-proliferative effects against various cancer cells

839672-57-0
DCC2985 L-161240

Potent inhibitor of LpxC and lipid A biosynthesis

183298-68-2
DCC2986 L-162782

Nonpeptide agonist of angiotensin AT1 receptor

169281-92-9
DCC2987 L17er4

Novel cell-permeable attenuated cationic amphiphilic lytic (ACAL) peptide, efficiently bring immunoglobulin G (IgG) and other functional proteins into cells

DCC2988 L2-4048

Novel Migration Inhibitory Factor (MIF) inhibitor, binding at the allosteric and tautomerase sites, blocking MIF's tautomerase CD74 receptor binding, and pro-inflammatory activities

DCC2989 L458-bpyne

Novel γ-secretase modulator photoaffinity probe, identifying distinct allosteric binding sites on presenilin that can be exploited to reduce levels of pathogenic Aβ species

1374647-07-0
DCC2990 L465046 (α-synuclein Amyloid Aggregation Inhibitor)

Novel inhibitor of α-synuclein amyloid aggregation for the treatment of Parkinson's disease

675171-18-3
DCC2991 L524-0366

Novel inhibitor of the TWEAK-Fn14 signaling cascade

951612-19-4
DCC2992 L61h46

Novel potent inhibitor of human pancreatic cancer cells

DCC2993 L-651392

Potent leukotriene inhibitor

93211-49-5
DCC2994 L-658758

Blocker of the activity of human neutrophil elastase (NE), human proteinase-3, human macrophage metalloelastase, mouse macrophage metalloelastase and Pseudomonas aeruginosa elastase

116507-04-1
DCC2995 L-663581

Novel partial agonist of the benzodiazepine receptor

122384-14-9
DCC2996 L-680833

Potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase (PMNL-E)

127063-08-5
DCC2997 L-682679

HIV protease inhibitor

126409-24-3
DCC2998 L-687306

Novel partial agonist of muscarinic M1 receptors

139346-23-9
DCC2999 L-696229

HIV-1 non-nucleoside reverse transcriptase inhibitor

135525-71-2
DCC3000 L-708906

Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1)

251963-74-3
DCC3001 L-731988

Inhibitor of Strand Transfer, Preventing Integration and Inhibiting HIV-1 Replication in Cells

251922-77-7
DCC3002 L-735821

Inhibitor of the KCNQ1 channel

170228-29-2
DCC3003 L-739758

Potent glycoprotein IIb/IIIa inhibitor

168157-33-3
DCC3004 L-744832

Ras farnesyltransferase inhibitor, inhibiting in p70(s6k) phosphorylation in mammary tumors, inducing tumor regression in transgenic mice by mediating alterations in both cell cycle control and apoptosis

1177806-11-9
DCC3005 L-749329

Dual ET(A)/ET(B) endothelin receptor antagonist

159590-37-1
DCC3006 L-768673

Class III antiarrhythmic agent, selectively blocking the slowly activating cardiac delayed rectifier potassium current Iks

177954-68-6
DCC3007 L-770644

Potent and selective agonist of the human beta3 adrenergic receptor

173901-95-6
DCC3008 L-778123 Featured

L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively.

183499-57-2
DCC3009 L-841411

Novel HIV-1 integrase strand transfer inhibitor (INSTI), stabilizing an integrase-single blunt-ended DNA complex

DCC3010 L-858051

Chemically-modified forskolin with greater stability and water solubility than the parent compound

115116-37-5
DCC3011 L-870812

Novel inhibitor of HIV-1 and SIV integrase

410545-90-3
DCC3012 L-94901

The first organ-selective thyromimetic, lowering plasma low density lipoprotein (LDL) cholesterol and raising plasma high density lipoprotein (HDL) cholesterol levels

DCC3013 L-97-1

Adenosine A1 receptor antagonist, reducing allergic responses to house dust mite in an allergic rabbit model of asthma, improving survival and protecting the kidney in a rat model of cecal ligation and puncture induced sepsis, also improving survival and

770703-20-3
DCC3014 Lamellarin D

Top1mt inhibitor, targeting mitochondrial DNA

97614-65-8
DCC3015 la-mem

Glutamate receptor antagonist and radical scavenging agent

1552275-56-5
DCC3016 Lanopepden Mesylate

Novel Peptide Deformylase Inhibitor against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus

1441390-17-5
DCC3017 laquinimod Sodium

Novel Modulator of autoimmune demyelination

248282-07-7
DCC3018 Largazole

Potent inhibitor of histone deacetylase

1009815-87-5
DCC3019 Las191859

Novel, potent and selective CRTh2 antagonist

DCC3020 Lasiojasmonate A

Natural fungal phytotoxin, activating the plant jasmonic acid pathway

DCC3021 Laspartomycin C

Lipopeptide antibiotic with activity against a range of Gram-positive bacteria including drug-resistant pathogens

DCC3022 Lassbio-1135

Novel dual TRPV1 antagonist and TNF-alpha production inhibitor

852453-71-5
DCC3023 Lassbio-1359

Novel adenosine receptor agonist, inducing relaxation of corpus cavernosum; Novel selective phosphodiesterase-​4 (PDE4) inhibitor associated with anti-​TNF-​α properties

1396397-19-5
DCC3024 Lassbio-1366

Novel Adenosine A2a Receptor Agonist, Attenuating the Progression of Monocrotaline-induced Pulmonary Hypertension

1396397-03-7
DCC3025 Lassbio-1524

Novel IKK-β inhibitor, reducing the secretion of TNF-α, IL-1β, IL-6, IL-12, IFN-γ and increased secretion of IL-10, protecting gastrointestinal homeostasis

DCC3026 Lassbio-1829 Hydrochloride

Novel orally active IKK2 inhibitor

1807810-16-7
DCC3027 Lassbio-1911

Novel Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitor

DCC3028 Latonduine A

Natural F508del-CFTR corrector, inhibiting both PARP-3 and -16, regulating the activity of the unfolded protein response activator inositol-requiring enzyme (IRE-1) via modulation of the level of its ribosylation by PARP-16

DCC3029 Latonduine B

Natural F508del-CFTR trafficking corrector, targeting poly(ADP-ribose) polymerase (PARP)

DCC3030 Latrunculin A

Disruptor of microfilament-mediated processes

76343-93-6
DCC3031 Laulimalide

Microtubule stabilzer, potently inhibiting cellular proliferation in cancer cell lines

115268-43-4
DCC3032 Laxaphycin A

Natural antifungal and cytotoxic agent

DCC3033 Laxaphycin B

Natural inhibitor of the proliferation of sensitive and resistant human cancer cell lines and this inhibitory activity is strongly increased in the presence of laxaphycin A

144941-08-2
DCC3034 Lb30870

Potent, orally active, selective and direct thrombin inhibitor

1583240-63-4
DCC3035 Lb30889

Prodrug of LB30870 as potent, orally active, selective and direct thrombin inhibitor

DCC3036 L-bmaa Hydrochloride

Neurotoxic amino acid

16012-55-8
DCC3037 Lc0024

Novel antibiofilm coating, covalently bindng to a titanium implant surface (LC0024-Ti)

DCC3038 Lcat Activator A

Novel activator of Lecithin:cholesterol acyltransferase (LCAT) including some familial mutations, by forming a hydrophobic adduct with Cys31

1000269-30-6
DCC3039 Lcb03-0110

Novel potent angiogenesis inhibitor, inhibiting VEGFR-2 and JAK/STAT3 signalling in primary cultured human endothelial cells and cancer cells

DCC3040 Lcl-peg3-n3

Novel clickable linker for estrogen receptor degraders

DCC3041 Lcrf-0004

Novel potent and selective RON receptor tyrosine kinase inhibitor

1229611-73-7
DCC3042 Ldc0496

Novel potent and selective covalent inhibitor of EGFR and Her2 exon20 insertion mutations, exhibiting selectivity over wild type EGFR and within the kinome

DCC3043 Ldc7559

Novel potent inhibitor of the NOX2-dependent oxidative burst in neutrophils by activating the glycolytic enzyme phosphofructokinase-1 liver type (PFKL) and dampening flux through the pentose phosphate pathway

2407782-01-6
DCC3044 Ldc8201

Novel potent and selective covalent inhibitor of EGFR and Her2 exon20 insertion mutations, exhibiting selectivity over wild type EGFR and within the kinome

DCC3045 Ldd-1819

Novel dual inhibitor of GSK-3β and aurora kinase A, increasing somatic cell plasticity and inhibiting tumorigenicity

DCC3046 Ldd970

Novel Aurora Kinase A Inhibitor

DCC3047 Lddn-0003499

Novel Src family tyrosine kinase inhibitor with anti-inflammatory effects in response to Aß stimulation of microglia

331662-51-2
DCC3048 Ldha-in-22y

Novel inhibitor of human lactate dehydrogenase A (LDHA)

<Prev1...109110111112113...127Next>